Global CGT CDMO Market Research Report 2023

Publication ID:

PB510241745

Publication Date:

October 11, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global CGT CDMO market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CGT CDMO 91制片厂.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CGT CDMO market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
WuXi AppTec
OBiO
GenScript
Porton
Lonza
Pharmaron
Catalent
Thermo Fisher
Oxford Biomedica (OXB)
Asymchem
Rentschler Biopharma
Novartis
Segment by Type
Immune Cells
Stem Cells
Viral Vectors
Plasmid DNA
Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CGT CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CGT CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immune Cells
1.2.3 Stem Cells
1.2.4 Viral Vectors
1.2.5 Plasmid DNA
1.3 Market by Application
1.3.1 Global CGT CDMO Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research and Academic Institutions
1.3.4 Hospital
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CGT CDMO Market Perspective (2018-2029)
2.2 CGT CDMO Growth Trends by Region
2.2.1 Global CGT CDMO Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CGT CDMO Historic Market Size by Region (2018-2023)
2.2.3 CGT CDMO Forecasted Market Size by Region (2024-2029)
2.3 CGT CDMO Market Dynamics
2.3.1 CGT CDMO Industry Trends
2.3.2 CGT CDMO Market Drivers
2.3.3 CGT CDMO Market Challenges
2.3.4 CGT CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CGT CDMO Players by Revenue
3.1.1 Global Top CGT CDMO Players by Revenue (2018-2023)
3.1.2 Global CGT CDMO Revenue Market Share by Players (2018-2023)
3.2 Global CGT CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CGT CDMO Revenue
3.4 Global CGT CDMO Market Concentration Ratio
3.4.1 Global CGT CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CGT CDMO Revenue in 2022
3.5 CGT CDMO Key Players Head office and Area Served
3.6 Key Players CGT CDMO Product Solution and Service
3.7 Date of Enter into CGT CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CGT CDMO Breakdown Data by Type
4.1 Global CGT CDMO Historic Market Size by Type (2018-2023)
4.2 Global CGT CDMO Forecasted Market Size by Type (2024-2029)
5 CGT CDMO Breakdown Data by Application
5.1 Global CGT CDMO Historic Market Size by Application (2018-2023)
5.2 Global CGT CDMO Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CGT CDMO Market Size (2018-2029)
6.2 North America CGT CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CGT CDMO Market Size by Country (2018-2023)
6.4 North America CGT CDMO Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CGT CDMO Market Size (2018-2029)
7.2 Europe CGT CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CGT CDMO Market Size by Country (2018-2023)
7.4 Europe CGT CDMO Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CGT CDMO Market Size (2018-2029)
8.2 Asia-Pacific CGT CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CGT CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific CGT CDMO Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CGT CDMO Market Size (2018-2029)
9.2 Latin America CGT CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CGT CDMO Market Size by Country (2018-2023)
9.4 Latin America CGT CDMO Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CGT CDMO Market Size (2018-2029)
10.2 Middle East & Africa CGT CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CGT CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa CGT CDMO Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 WuXi AppTec
11.1.1 WuXi AppTec Company Detail
11.1.2 WuXi AppTec Business Overview
11.1.3 WuXi AppTec CGT CDMO Introduction
11.1.4 WuXi AppTec Revenue in CGT CDMO Business (2018-2023)
11.1.5 WuXi AppTec Recent Development
11.2 OBiO
11.2.1 OBiO Company Detail
11.2.2 OBiO Business Overview
11.2.3 OBiO CGT CDMO Introduction
11.2.4 OBiO Revenue in CGT CDMO Business (2018-2023)
11.2.5 OBiO Recent Development
11.3 GenScript
11.3.1 GenScript Company Detail
11.3.2 GenScript Business Overview
11.3.3 GenScript CGT CDMO Introduction
11.3.4 GenScript Revenue in CGT CDMO Business (2018-2023)
11.3.5 GenScript Recent Development
11.4 Porton
11.4.1 Porton Company Detail
11.4.2 Porton Business Overview
11.4.3 Porton CGT CDMO Introduction
11.4.4 Porton Revenue in CGT CDMO Business (2018-2023)
11.4.5 Porton Recent Development
11.5 Lonza
11.5.1 Lonza Company Detail
11.5.2 Lonza Business Overview
11.5.3 Lonza CGT CDMO Introduction
11.5.4 Lonza Revenue in CGT CDMO Business (2018-2023)
11.5.5 Lonza Recent Development
11.6 Pharmaron
11.6.1 Pharmaron Company Detail
11.6.2 Pharmaron Business Overview
11.6.3 Pharmaron CGT CDMO Introduction
11.6.4 Pharmaron Revenue in CGT CDMO Business (2018-2023)
11.6.5 Pharmaron Recent Development
11.7 Catalent
11.7.1 Catalent Company Detail
11.7.2 Catalent Business Overview
11.7.3 Catalent CGT CDMO Introduction
11.7.4 Catalent Revenue in CGT CDMO Business (2018-2023)
11.7.5 Catalent Recent Development
11.8 Thermo Fisher
11.8.1 Thermo Fisher Company Detail
11.8.2 Thermo Fisher Business Overview
11.8.3 Thermo Fisher CGT CDMO Introduction
11.8.4 Thermo Fisher Revenue in CGT CDMO Business (2018-2023)
11.8.5 Thermo Fisher Recent Development
11.9 Oxford Biomedica (OXB)
11.9.1 Oxford Biomedica (OXB) Company Detail
11.9.2 Oxford Biomedica (OXB) Business Overview
11.9.3 Oxford Biomedica (OXB) CGT CDMO Introduction
11.9.4 Oxford Biomedica (OXB) Revenue in CGT CDMO Business (2018-2023)
11.9.5 Oxford Biomedica (OXB) Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Detail
11.10.2 Asymchem Business Overview
11.10.3 Asymchem CGT CDMO Introduction
11.10.4 Asymchem Revenue in CGT CDMO Business (2018-2023)
11.10.5 Asymchem Recent Development
11.11 Rentschler Biopharma
11.11.1 Rentschler Biopharma Company Detail
11.11.2 Rentschler Biopharma Business Overview
11.11.3 Rentschler Biopharma CGT CDMO Introduction
11.11.4 Rentschler Biopharma Revenue in CGT CDMO Business (2018-2023)
11.11.5 Rentschler Biopharma Recent Development
11.12 Novartis
11.12.1 Novartis Company Detail
11.12.2 Novartis Business Overview
11.12.3 Novartis CGT CDMO Introduction
11.12.4 Novartis Revenue in CGT CDMO Business (2018-2023)
11.12.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

WuXi AppTec
OBiO
GenScript
Porton
Lonza
Pharmaron
Catalent
Thermo Fisher
Oxford Biomedica (OXB)
Asymchem
Rentschler Biopharma
Novartis

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.